The two companies have formed Oblenio Bio to develop a tri-specific T-cell engager The U.S. company Aditum Bio and Chinese ...
The US biopharma will discontinue development of the Exondys 51 (eteplirsen) follow up treatment to focus on other treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback